Terence Flynn
Stock Analyst at Morgan Stanley
(4.18)
# 430
Out of 5,072 analysts
216
Total ratings
60.55%
Success rate
10.24%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Overweight | $1,171 → $1,290 | $1,104.34 | +16.81% | 23 | Nov 24, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $54 → $26 | $9.48 | +174.26% | 4 | Nov 18, 2025 | |
| OGN Organon & Co. | Maintains: Equal-Weight | $10 → $9 | $7.74 | +16.28% | 11 | Nov 11, 2025 | |
| AMGN Amgen | Maintains: Equal-Weight | $333 → $329 | $344.57 | -4.52% | 10 | Nov 5, 2025 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $98 → $100 | $104.63 | -4.43% | 18 | Nov 3, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $178 → $190 | $207.56 | -8.46% | 25 | Oct 15, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Equal-Weight | $16 → $15 | $17.20 | -12.79% | 6 | Oct 14, 2025 | |
| PFE Pfizer | Maintains: Equal-Weight | $33 → $32 | $25.71 | +24.47% | 19 | Oct 10, 2025 | |
| RPRX Royalty Pharma | Maintains: Overweight | $55 → $54 | $39.84 | +35.54% | 13 | Oct 10, 2025 | |
| BNTX BioNTech SE | Maintains: Overweight | $133 → $131 | $102.70 | +27.56% | 5 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $439 → $438 | $432.17 | +1.35% | 1 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $328 → $435 | $488.43 | -10.94% | 11 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $22 | $7.64 | +187.96% | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $255 | $227.66 | +12.01% | 18 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $34 | $49.25 | -30.96% | 11 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $12.42 | -11.43% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $22 | $25.56 | -13.93% | 6 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $53.30 | -39.96% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $8.52 | +29.11% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $118 | $34.22 | +244.83% | 1 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $2.68 | +198.51% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $181.94 | +139.64% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $445.12 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.82 | - | 1 | Jul 21, 2017 |
Eli Lilly and Company
Nov 24, 2025
Maintains: Overweight
Price Target: $1,171 → $1,290
Current: $1,104.34
Upside: +16.81%
Biohaven
Nov 18, 2025
Maintains: Overweight
Price Target: $54 → $26
Current: $9.48
Upside: +174.26%
Organon & Co.
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $10 → $9
Current: $7.74
Upside: +16.28%
Amgen
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $333 → $329
Current: $344.57
Upside: -4.52%
Merck & Co.
Nov 3, 2025
Maintains: Equal-Weight
Price Target: $98 → $100
Current: $104.63
Upside: -4.43%
Johnson & Johnson
Oct 15, 2025
Maintains: Equal-Weight
Price Target: $178 → $190
Current: $207.56
Upside: -8.46%
Nurix Therapeutics
Oct 14, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $17.20
Upside: -12.79%
Pfizer
Oct 10, 2025
Maintains: Equal-Weight
Price Target: $33 → $32
Current: $25.71
Upside: +24.47%
Royalty Pharma
Oct 10, 2025
Maintains: Overweight
Price Target: $55 → $54
Current: $39.84
Upside: +35.54%
BioNTech SE
Oct 10, 2025
Maintains: Overweight
Price Target: $133 → $131
Current: $102.70
Upside: +27.56%
Oct 10, 2025
Maintains: Equal-Weight
Price Target: $439 → $438
Current: $432.17
Upside: +1.35%
Oct 10, 2025
Maintains: Equal-Weight
Price Target: $328 → $435
Current: $488.43
Upside: -10.94%
Aug 15, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $7.64
Upside: +187.96%
Aug 1, 2025
Maintains: Overweight
Price Target: $250 → $255
Current: $227.66
Upside: +12.01%
Jul 10, 2025
Maintains: Underweight
Price Target: $36 → $34
Current: $49.25
Upside: -30.96%
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $12.42
Upside: -11.43%
May 9, 2025
Maintains: Overweight
Price Target: $24 → $22
Current: $25.56
Upside: -13.93%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $53.30
Upside: -39.96%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $8.52
Upside: +29.11%
Sep 23, 2024
Initiates: Overweight
Price Target: $118
Current: $34.22
Upside: +244.83%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $2.68
Upside: +198.51%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $181.94
Upside: +139.64%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $445.12
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $8.82
Upside: -